Source-grounded facts extracted from Jazz Pharmaceuticals plc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Anne O'Riordan departed as Director at Jazz Pharmaceuticals plc.
“On May 25, 2026, Anne O’Riordan, a Class III director whose term expires at the Jazz Pharmaceuticals plc (the “Company”) 2026 annual meeting of shareholders, has informed the board of directors (the “Board”) that she will not stand for re-election.”
Jazz Pharmaceuticals plc reported first quarter of 2026 (1Q26) results: revenue $1.1 billion, EPS $4.43 / $6.34. Guidance reaffirmed.
“filing. --- EX-99.1 (EX-99.1) --- Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results – Strong commercial execution across franchises with total revenues of $1.1 billion (+19% YoY) – – Zanidatamab HER2+ 1L GEA sBLA granted Priority Review; PDUFA date of August 25, 2026 – – Xywav ® revenues grew 18% YoY with 425 net patient adds – – Epidiolex ®”
Catherine Sohn departed as Director at Jazz Pharmaceuticals plc.
“On May 31, 2024, Catherine Sohn, Pharm.D. notified the board of directors (the “Board”) of Jazz Pharmaceuticals plc (the “Company”), that she is retiring and will not stand for re-election to the Board, when her term expires, at the Company’s 2024 annual general meeting of shareholders.”
Jazz Pharmaceuticals plc updated its first quarter of 2024 guidance (reaffirmed).
“Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the first quarter of 2024 and affirmed guidance for 2024.”
Peter Gray resigned as Director at Jazz Pharmaceuticals plc.
“Peter Gray notified the Board that he will not stand for re-election to the Board, when his term expires, at the 2024 Annual Meeting.”
Patrick Kennedy was appointed as Director at Jazz Pharmaceuticals plc.
“appointed Patrick Kennedy to the Board, effective as of March 1, 2024, as a Class I director”
Philip Johnson was appointed as Executive Vice President and Chief Financial Officer at Jazz Pharmaceuticals plc.
“On February 21, 2024, Jazz Pharmaceuticals plc (the “Company”) announced the appointment of Philip Johnson as the Company’s Executive Vice President and Chief Financial Officer, effective as of March 1, 2024.”
Jazz Pharmaceuticals plc amended credit facility with Bank of America, N.A. at Term SOFR plus 3.00% (with a floor of 0.50%) or the prime lending rate plus 2.00.
“The applicable margin for the Tranche B-1 Dollar Term Loans is 3.00% (in the case of Term SOFR borrowings) and 2.00% (in the case of borrowings at the prime lending rate), a decrease of 50 basis points from the applicable margin on the Initial Dollar Term Loans”
Jazz Pharmaceuticals plc incurred term loan of $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans maturing May 5, 2028.
“Jazz Lux borrowed $201,909,488.38 aggregate principal amount of additional Tranche B-1 Dollar Term Loans”
Jazz Pharmaceuticals plc amended Repricing Amendment with Bank of America, N.A., as administrative agent and U.S. Bank Trust Company, National Association, as collateral trustee (effective 2024-01-19).
“abilité limitée ) incorporated and existing under the laws of Luxembourg (“Jazz Lux”) and wholly owned subsidiary of Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in Ireland (the “Company”), entered into an amendment (the “Repricing Amendment”) to the Credit Agreement, dated May 5, 2021, by and among Jazz Lux and certain other subsidiaries of the Company, as borrowers (collectively with the Company and Jazz Lux, the “Borrowers”), the lenders and issuing banks from time to time party thereto, Bank of America, N.A., as administrative agent and U.S.”
Jazz Pharmaceuticals plc updated its the year ended December 31, 2024 guidance (initiated).
“the Company's expectations that its key growth drivers, Xywav, Epidiolex, and Rylaze, are expected to have combined double-digit percentage revenue growth in 2024, and (iii) the Company's expectations with respect to the growth of high-sodium oxybate authorized generic royalty revenue for the year ended December 31, 2024”
Jazz Pharmaceuticals plc updated its the year ended December 31, 2023 guidance (reaffirmed).
“the Company's expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance range for the year ended December 31, 2023”
Kim Sablich departed as Executive Vice President and General Manager, US at Jazz Pharmaceuticals plc.
“On December 15, 2023, Jazz Pharmaceuticals plc (the “Company”) announced that Kim Sablich, Executive Vice President and General Manager, US, will be departing the Company, and that effective as of December 31, 2023, Ms. Sablich will no longer serve in that role or as an executive officer of the Company.”
Jazz Pharmaceuticals plc updated its the quarter ended September 30, 2023 guidance (raised).
“On November 8, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended September 30, 2023.”
Patricia Carr was appointed as principal financial officer (interim) at Jazz Pharmaceuticals plc.
“Effective as of October 1, 2023, Patricia Carr, the Company’s Senior Vice President and Chief Accounting Officer, will serve as the Company’s principal financial officer on an interim basis while the Company conducts a search for Ms. Galá’s replacement as the Company’s Executive Vice President and Chief Financial Officer.”
Renée Galá was appointed as President and Chief Operating Officer at Jazz Pharmaceuticals plc.
“On September 11, 2023, the Board appointed Renée Galá as the Company’s President and Chief Operating Officer, effective as of October 1, 2023, to succeed Mr. Swisher as the Company’s President and Chief Operating Officer.”
Daniel Swisher, Jr. departed as President and Chief Operating Officer at Jazz Pharmaceuticals plc.
“Mr. Swisher will cease performing the duties and responsibilities of the Company’s President and Chief Operating Officer and will resign from any office or directorship at any affiliated entity of the Company, effective October 1, 2023.”
Jazz Pharmaceuticals plc updated its the second quarter of 2023 guidance (raised).
“On August 9, 2023, Jazz Pharmaceuticals plc (the “Company”) issued a press release (the “Press Release”) announcing financial results for the Company for the quarter ended June 30, 2023.”
Jazz Pharmaceuticals plc reported full year 2023 results: revenue $3,675 to $3,875 million. Guidance initiated.
“2023 total revenue guidance of $3,675 to $3,875 million”
Jazz Pharmaceuticals plc reported full year and fourth quarter ended December 31, 2022 results: revenue $3.7 billion.
“Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021”
Jazz Pharmaceuticals plc updated its year ended December 31, 2022 guidance (reaffirmed).
“the Company’s expectations that it will meet its previously announced total, neuroscience and oncology revenue guidance ranges for the year ended December 31, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.